5 | CONCLUSION
Enhanced knowledge of healthcare providers such as physicians and
dentists about bisphosphonates can decrease the incidence of BRONJ and
lead to a more favorable recovery.26 Also, improved
instruction of patients regarding the use and side effects of
bisphosphonates by physicians and dentists can promote the quality of
care and decrease the side effects of medical and dental
treatments.33 The current results showed that
physicians practicing in Tehran had some knowledge about dental
considerations in patients taking bisphosphonates; however, their lack
of knowledge about some items was obvious.
Authorship:
TP was involved in the conception and design of the work, data
collection, drafting of the manuscript, critical revision of the
manuscript, and final approval of the version to be published.
ND was involved in the conception and design of the work, data
collection, drafting of the manuscript, critical revision of the
manuscript, and final approval of the version to be published.
XM was involved in the conception and design of the work, data
collection, drafting of the manuscript, critical revision of the
manuscript, and final approval of the version to be published.
ACNOWLEDGEMENTS: We wish to thank the physicians who took part in the
study.
Conflict of Interest: None declared
Funding Information: No sources of funding are declared for this study.
References
1- Chapurlat RD, Delmas PD, Liens D, Meunier PJ. Long-term effects of
intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res.
1997; 12(10):1746-1152.
2- Verenna M, Zucchi F, Ghiringhelli D, Binelli L, Bevilacqua M, Bettica
P. Intravenous clodronate in the treatment of reflex sympathetic
dystrophy syndrome. A randomized, double blind, placebo controlled
study. J Rheumatol. 2000; 27(6):1477-1483.
3- Rosenberg TJ, Ruggiero S. Osteonecrosis of the jaws associated with
the use of bisphosphnates. J Oral Maxillofac Surg. 2003; 61(8):60-61.
4- Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of
the jaws associated with the use of bisphosphonates: a review of 63
cases. J Oral Maxillofac Surg. 2004; 62(5):527-534.
5- Greenberg MS. Intravenous bis-phosphonates and osteonecrosis. Oral
Surg Oral Med Oral Radiol Endod. 2004; 93(3):259-260.
6- Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced
exposed bone (osteonecrosis osteopetrosis) of the jaws: risk factors,
recognition, prevention and treatment, J Oral Maxillofac Surg. 2005;
63(11):1567-1575.
7- Kim JW, Jeong SR, Kim SJ, Kim Y. Perceptions of medical doctors on
bisphosphonate-related osteonecrosis of the jaw. BMC Oral Health. 2016;
16(1):92.
8- Reid IR, Cornish J. Epidemiology and pathogenesis of osteonecrosis of
the jaw. Nat Rev Rheumatol. 2012; 8:90–96.
9- Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B,
O’Ryan F. American Association of Oral and Maxillofacial Surgeons
position paper on medication-related osteonecrosis of the jaw–2014
update. J Oral Maxillofac Surg. 2014; 72:1938–1956.
10- Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F,
Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watt NB, Brandi ML, Peters
E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan
SL, Obermayer-Pietsch B, et al. Diagnosis and management of
osteonecrosis of the jaw: a systematic review and international
consensus. J Bone Miner Res. 2015; 30:3–23.
11- Lam DK, Sandor GK, Holmes HI, Evans AW, Clokie CM. A review of
bisphosphonate-associated osteonecrosis of the jaws and its management.
J Can Dent Assoc 2007; 73:417–422.
12- Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D,
Gagel RF, Gilsanz V, Guise T, Koka S, et al. Bisphosphonate-associated
osteonecrosis of the jaw: report of a task force of the American Society
for Bone and Mineral Research. J Bone Miner Res 2007; 22:1479–1491.
13- Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review
of the literature on osteonecrosis of the jaw in patients with
osteoporosis treated with oral bisphosphonate: prevalence, risk factors,
and clinical characteristics. Clin Ther 2009; 29:1548–1558.
14- Paeng JY. Diagnosis and management of BRONJ (bisphosphonate related
osteonecrosis of jaw). J Korean Dent Assoc 2011; 49:378–388.
15- Choi SW, Kim SR, Lee KB. Osteonecrosis of the jaw in a patient with
osteoporosis treated with oral bisphosphonates. J Korean Orthop Assoc
2010; 45:151–154.
16- Khan AA, Sandor GK, Dore E. Canadian consensus practice guidelines
for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol
2008; 35(7):1391-1397.
17- Epstein JB, Kish RV, Hallajian L, Sciubba J. Head and neck oral and
orophryngeal cancer: a review of medicolegal cases. Oral Surg Oral Med
Oral Pathol Oral Radiol 2015; 119:177-186.
18- Hristamyan-Cilev MA, Pechalova PP, Raycheva RD, Hristamyan VP,
Kevorkyan AK, Stoilova YD. Bisphosphonate-associated osteonecrosis of
the jaws: a survey of the level of knowledge of dentists about the risks
of bisphosphonate therapy. Folia Med (Plovdiv) 2019;
1; 61(2):303-311.
19- Senturk MF, Cimen E, Tuzuner Oncul AM, Cambazoglu M. Oncologist’s
awareness about bisphosphonate related osteonecrosis of the jaws. J Pak
Med Assoc 2016; 66(7):880-883.
20- Al-Mohaya MA, Al-Khashan HI, Mishriky AM, Al-Otaibi LM. Physicians’
awareness of bisphosphonates-related osteonecrosis of the jaw. Saudi Med
J 2011; (8):830-835.
21- Bauer JS, Beck N, Kiefer J, Stockmann P, Wichmann M, Eitner S.
Awareness and education of patients receiving bisphosphonates. J
Craniomaxillofac Surg 2012; 40:277-282.
22- Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM,
Castronovo V, Green JR. Novel antiangiogenic effects of the
bisphosphonate compound zolendronic acid. J Pharmacol Exp Ther 2002;
302:1055-106.
23- Ruggiero SL, Dodson TB, Assael LA, Landsberg R, Mars RE, Mehrotra B.
American Association of oral and maxillofacial surgeons’ positions paper
on bisphosphonate-related osteonecrosis of the jaws–2009 update. J Oral
Maxillofac Surg 2009; 67:2-12.
24- Moinzadeh AT, Shemesh H, Neirynck NA, Aubert C, Wesselink PR.
Bisphosphonates and their clinical implications in endodontic therapy.
Int Endod J 2013; 46(5):391-398.
25- Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S,
Andreadis CG, Boukovinas I, Koloutsos GE, Teleioudis Z, Kitikidou K,
Paraskevopoulos P, Zervas K, Antoniadaes K. Longitudinal cohort study of
risk factors in cancer patients of bisphosphonate-related osteonecrosis
of the jaw. J Clin Oncol 2009; 27:5356-5362.
26- Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT,
Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F,
Fizazi K, Zhou L, Daniels A, Carriere P, Dansey R. Incidence, risk
factors, and outcomes of osteonecrosis of the jaw: integrated analysis
from three blinded active-controlled phase III trials in cancer patients
with bonemetastases. Ann Oncol 2012; 23:1341-1347.
27- Fehm T, Beck V, Banys M, Lipp HP, Hairass M, Reinert S, Solomayer
EF, Wallwiener D, Krimmel M. Bisphosphonate-induced osteonecrosis of the
jaw (ONJ): Incidence and risk factors in patients with breast cancer and
gynecological malignancies. Gynecol Oncol 2009; 112:605-609.
28- Dickinson M, Prince HM, Kirsa S, Zannettino A, Gibbs SD, Mileshkin
L, OGrady J, Seymour JF, Szer J, Horvath N, Joshua DE. Osteonecrosis of
the jaw complicating bisphosphonate treatment for bone disease in
multiple myeloma: an overview with recommendations for prevention and
treatment. Intern Med J 2009; 39:304-316.
29- Kwon YD, KimYR, Choi BJ, Lee DW, Kim DY. Oral bis-phosphonate
related osteonecrosis of the jaws: favorable outcome after
bisphosphonate holiday. Quintessence Int 2009; 40:277-278.
30- .McLeod NM, Brennan PA, Ruggiero SL. Bisphosphonate osteonecrosis of
the jaw: a historical and contemporary review. Surgeon 2012; 10:36-42.
31.Vescovi P, Merigo E, Meleti M, Manfredi M, Guidotti R, Nammour S.
Bisphosphonates-related osteonecrosis of the jaws: a concise review of
the literature and a report of a single-centre experience with 151
patients. J Oral Pathol Med 2012; 41:214-221.
32- Patel V, McLeod NM, Rogers SN, Brennan PA. Bisphosphonate
osteonecrosis of the jaw–a literature review of UK policies versus
international policies on bisphosphonates, risk factors and prevention.
Br J Oral Maxillofac Surg 2011; 49:251-257.
33- Migliorati CA, Mattos K, Palazzolo MJ. How patients’ lack of
knowledge about oral bisphosphonates can interfere with medical and
dental care. J Am Dent Assoc 2010; 141(5):562-566